Immorna (Hangzhou) Biotechnology, an mRNA-based vaccine developer based in Hangzhou, has announced the enrollment of the first patient in a Phase I clinical study to assess the safety and efficacy of JCXH-211, a potential cancer therapeutic, in malignant solid tumors in China. The study will determine the recommended Phase II dosage for the molecule.
Study Details
The open-label, dosage escalation, and dosage expansion Phase I study is expected to enroll 156 patients with malignant solid tumors, including head and neck cancer, liver cancer, melanoma, triple-negative breast cancer, and esophageal cancer. Participants will be those who have progressed after standard treatment (except for the best supportive treatment) or who are intolerant of standard treatment.
JCXH-211 Profile
JCXH-211 is described as a best-in-class self-replicating RNA (srRNA) product capable of expressing human interleukin-12 (IL-12) in vivo for extended periods. This makes it potentially suitable for the treatment of a variety of solid tumors. Preclinical studies have shown that the drug effectively kills tumor cells, eliminates distal tumors, and prevents tumor recurrence in mouse models, while maintaining a good safety profile.
Significance of the Study
The initiation of this Phase I clinical trial marks a significant milestone in the development of JCXH-211, highlighting Immorna Therapeutics’ commitment to advancing innovative mRNA-based cancer treatments. The study aims to provide valuable data on the drug’s safety and efficacy, paving the way for further clinical development.-Fineline Info & Tech
